KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abbott Laboratories (ABT) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to $0.25.

  • Abbott Laboratories' Debt to Equity fell 3254.15% to $0.25 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.25, marking a year-over-year decrease of 3254.15%. This contributed to the annual value of $0.29 for FY2024, which is 2200.24% down from last year.
  • Latest data reveals that Abbott Laboratories reported Debt to Equity of $0.25 as of Q3 2025, which was down 3254.15% from $0.26 recorded in Q2 2025.
  • Abbott Laboratories' Debt to Equity's 5-year high stood at $0.57 during Q4 2021, with a 5-year trough of $0.25 in Q3 2025.
  • Its 5-year average for Debt to Equity is $0.42, with a median of $0.45 in 2023.
  • As far as peak fluctuations go, Abbott Laboratories' Debt to Equity tumbled by 133.57% in 2023, and later tumbled by 3254.15% in 2025.
  • Over the past 5 years, Abbott Laboratories' Debt to Equity (Quarter) stood at $0.57 in 2021, then dropped by 16.9% to $0.48 in 2022, then dropped by 20.53% to $0.38 in 2023, then dropped by 22.0% to $0.29 in 2024, then fell by 14.39% to $0.25 in 2025.
  • Its Debt to Equity was $0.25 in Q3 2025, compared to $0.26 in Q2 2025 and $0.27 in Q1 2025.